George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
At the time of the Capital Raise, Lindy did say H1 2024 for SCIB1 data but it’s now Q3, so some slippage there. I’d also have preferred to have seen iSCIB recruitment has started, rather than expected to start in Q1 (given it’s nearly Feb). Depends how you define “started” I guess.
However, the RNS tells the market where we are and nowt to worry about imo.
Can’t see why Redmile would be in a hurry. They have over £2.5B in holdings, so little Scancell right now, are small beer to them really.
Would be like trying to cancel your bet on a horse running well, that is in a prominent position in its race, with a couple of fences still to jump. Might fall yes but very much in the mix with a chance to win the prize money.
All imo of course ;-)
Not sure why this article has only just been published given it’s not new news (unless there is something different behind the paywall). However it’s all good publicity.
https://www.oxfordmail.co.uk/news/24078268.review-abba-voyage-created-help-oxford-tech-firm/
Reasonable to expect the same format / structure, as the Results issued on 31/10.
Highlights / Update sections on:
SCOPE
Modi-1
Antibodies
Corporate
Financials
TF is right imo where he says it’s not just about the subject matter but how it is written. As an example for Financials, I would hope the emphasis is on how well the Company is now funded and what that will enable them to do. Otherwise news articles will just lead with any losses.
HAGW & roll-on Tues (maybe Monday :-))
I wonder if /when we can expect changes / updates to the clinicaltrials.gov & also Cancer Research web pages, in line with recent iSCIB+ announcements? Always seems to be quite a lag but would assume they will have to catch up at some point.